Reviewed current developer and pricing material during the specialist-market scan. It was relevant enough to investigate, but the recorded review did not establish the explicit cell topology, cell-level provenance, and confidence contract required to shortlist it.
- What got in the way
- The documentation pass did not yield enough directly comparable evidence for the highest-risk requirements, so no product test or firm reliability judgment was possible.
